Low-dose ritonavir moderately enhances nelfinavir exposure

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 2, 2002, Pages 123-132

  Kurowski, Michael ^a,b,c,d,e   Kaeser, Benoite ^a,b,c,d   Sawyer, Anthony ^a,b,c,d   Popescu, Matei ^a,b,c,d   Mrozikiewicz, Alexander ^a,b,c,d  

^a HIV Laboratory Therapia GmbH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c CITY UNIVERSITY   (United Kingdom)

^d ADAM MICKIEWICZ UNIVERSITY   (Poland)

^e Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DRUG METABOLITE; INDINAVIR; NELFINAVIR; PARACETAMOL; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HUMANS; MALE; NELFINAVIR; RITONAVIR; TIME FACTORS;

EID: 0036694265     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.126178     Document Type: Article

References (37)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Changing patterns of mortality across Europe in patients infected with HIV-1
3. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
4. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
5. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
6. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities
7. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
8. Nelfinavir: An update on its use in HIV infection
9. Nelfinavir mesylate: A protease inhibitor
10. Lack of pharmacokinetic interaction between nelfinavir and nevirapine
11. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
12. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with "BABY-DOSE" ritonavir
13. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
14. Effects of the HIV-1 protease inhibitor, 141W94, and rifampin, and rifabutin on P450 3A4 activity as measured by erythromycin breath test
15. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomised trial
16. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
17. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement
18. US approved labeling for Kalebra
19. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
20. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice-daily dosing regimens in HIV-1-infected individuals
21. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg RTV 200 mg qd given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naïve HIV-1 infected adults over 12 weeks (APV2001)
22. US approved labelling for NORVIR
23. Efficacy of a five-drug combination of ritonavir, saquinavir and efavirenz in patients who failed on conventional triple drug regime: Phenotypic resistance to protease inhibitors predicts outcome of therapy
24. Effect of food on the pharmacokinetics of nelfinavir (Viracept) administered twice daily
25. Simultaneous determination of protease inhibitors using LC-tandem mass spectrometry
26. Ritonavir: New drug profile
27. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
28. Improved tolerability of ritonavir derived from pharmacokinetic principles
29. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection
30. Steady-state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV), and the nelfinavir active metabolite M8 (AG1402)
31. Apparent genetic polymorphism in nelfinavir metabolism: Evaluation of clinical relevance
32. Nelfinavir mesylate
33. The role of CYP2C19 in the formation of nelfinavir hydroxy-t-butylamide (M8): In vitro/in vivo correlation
34. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
35. US approved labelling for Viracept